REG - Verici Dx PLC - FY25 Trading Update

Verici DxAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260205:nRSE7865Ra&default-theme=true

RNS Number : 7865R  Verici Dx PLC  05 February 2026

 

Verici Dx plc

("Verici Dx" or the "Company")

 

FY25 Trading Update

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, provides a trading update for the year ended 31 December
2025 ("FY25"), a year of strong growth and commercial progress for the
Company.

 

Financial highlights

·      Total unaudited revenues(1) of $3.8m (2024: $3.3m) comprising:

o  $3.0m from recognised revenue of Tutivia (2024: $Nil). $3.2m worth of
tests were ordered during the year

o  $0.8m from license income (2024: $3.3m), reflecting the expected timing of
milestone payments under the outlicensed contract

·      Unaudited cash at year-end of $3.3m (2024: $4.1m), which is
slightly ahead of expectations, with $1.6m accounts receivable (2024: $Nil)
which continues to support expected cash runway into H2 2026 as previously
communicated.

 

Operational highlights

·      Significant commercial progress across the year with first
revenues from Tutivia™ test results.

·      Secured Medicare coverage for Tutivia™ covering a national
estimate of 68% of all US transplant tests and greatly improving patient
access.

·      Milestone receipt of $0.8m from Thermo Fisher Scientific for the
product licensing of PTRA (Clarava).

·      Continued increase in test adoption with:

o 1,173 Tutivia™ tests ordered in FY25 (Q4: 296) compared to 334 over the
whole of FY24.

·    Expansion in centres using Tutivia(TM) for a total of 34 representing
18% of annual kidney transplants in the US, with the addition of 4 new
ordering centres in Q4.

·    Signed a Provider Participation Agreement with Prime Health Services,
a dynamic healthcare technology US based company focused on delivering
innovative, data-driven solutions through its Preferred Provider Organization
('PPO') network.

·    Additional commercial team member added.

·    Contract signed with Blue Cross Blue Shield ("BCBS") of Illinois,
announced separately today, with contracted pricing across multiple lines of
business, giving in-network status for BCBS covered patients and providing the
Company with access to open contract processes with other BCBS entities.

 

(1) Revenue is reimbursed from two core types of payor: Medicare and
commercial payors. For Medicare patients, there is a fixed price for the test.
For commercial payors, there are a number of factors which determine whether,
and for how much, the test is reimbursed, which can vary by commercial payor.
Revenue recognition therefore requires a significant amount of judgement and
estimation, as we continue to gather information to inform a reasonable
average reimbursement from these commercial payors. This assessment is
monitored monthly, with revisions made based on the actual reimbursement price
achieved and denial rates, once known with reasonable certainty.

 

Notice of Results

The Company currently expects to announce full year results no later than May
2026. A further announcement confirming a date for publication of the audited
results will be issued in due course.

 

Sara Barrington, Chief Executive Officer, said: "We are proud to have achieved
substantial growth in FY25, reflected in the continued adoption of Tutivia™
and an increase in sales across the year. Whilst recognised Tutivia™
revenues of $3.0m were slightly behind market expectations for the full year,
we continue to see strong testing volume acceleration beyond the $3.2m of
orders received during the year. We are confident that our clinical and
regulatory foundations will continue to show successful commercial traction
across 2026 and beyond."

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated adviser, Joint Broker)                     Tel: +44 (0)20 7496 3000
 Phil Davies

 Oberon Capital (Joint Broker)                 Tel: +44 (0)20 3179 0500
 Mike Seabrook / Adam Pollock

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
 Alice Woodings / Rachel Broad                 Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393

 

 

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care
for transplant patients. The company combines multiomic analysis with
proprietary artificial intelligence to deliver predictive, actionable,
data-driven intelligence that reflects the complexity and heterogeneity of
transplant patients, enabling clinicians to optimize therapy, guide biopsy
decisions, and stratify risk with greater confidence.

 

Operating at the intersection of laboratory and data science, Verici Dx
develops complex models that answer the clinical questions that matter most
with unrivaled clarity and precision. All tests are built to rigorous
scientific standards, validated across inclusive, and real-world patient
populations to ensure clinical relevance and reliability. Verici Dx's lead
product, Tutivia™, is a post-kidney transplant test focused on early
detection of acute rejection.

 

The company is UK headquartered in Cardiff for the UK, and in Franklin,
Tennessee for the U.S. For more information, please visit
https://vericidx.com/ (https://vericidx.com/) and follow us on LinkedIn
(https://www.linkedin.com/company/verici-dx/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTAKQBPDBKBOBK



            Copyright 2019 Regulatory News Service, all rights reserved